| Product Specific References | - Judd NP, Allen CT, Winkler AE, Uppaluri R. Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol Head Neck Surg. 2012 Sep;147(3):493-500. doi: 10.1177/0194599812442037. Epub 2012 Mar 19. PubMed PMID: 22434099; PubMed Central PMCID: PMC6346425.
- Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012 Jan 1;72(1):365-74. doi: 10.1158/0008-5472.CAN-11-1831. Epub 2011 Nov 15. PubMed PMID: 22086849; PubMed Central PMCID: PMC3286642.
- Onken MD, Winkler AE, Kanchi KL, Chalivendra V, Law JH, Rickert CG, Kallogjeri D, Judd NP, Dunn GP, Piccirillo JF, Lewis JS Jr, Mardis ER, Uppaluri R. A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res. 2014 Jun 1;20(11):2873-84. doi: 10.1158/1078-0432.CCR-14-0205. Epub 2014 Mar 25. PubMed PMID: 24668645; PubMed Central PMCID: PMC4096804.
- Robbins Y, Greene S, Friedman J, et al. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. Elife. 2020;9:e54854. Published 2020 Jul 7. View article
- Anderson K, Ryan N, Alkhimovitch A, Siddiqui A, Oghumu S. Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity. Cancers (Basel). 2021 Feb 25;13(5):953. View article
- Kono M, Saito S, Egloff AM, Allen CT, Uppaluri R. The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations. Oral Oncol. 2022 Jul 9;132:106012. doi: 10.1016/j.oraloncology.2022.106012. Epub ahead of print. PMID: 35820346.
|
|---|
